Of note, CDK1 (cyclin-dependent kinase 1), which is downregulated by the flavonoid compound juglanin (Table 1), was found to be overexpressed in invasive breast cancer (Table 2); Izadi et al. suggest that CDK1 is the best CDK target for breast cancer therapy [86]. This evidence concerns the gene CDK1 and breast carcinoma.